Jiang Tao, Xie Pengfeng, Liu Hongchen
Professor, Department of Stomatology, Chinese PLA General Hospital, Beijing, China; Department of General Dentistry, Jinan Stomatological Hospital, Jinan, Shandong, China.
Resident, Department of Oral and Maxillofacial Surgery, Jinan Stomatological Hospital, Jinan, Shandong, China.
J Oral Maxillofac Surg. 2016 Mar;74(3):650-7. doi: 10.1016/j.joms.2015.09.016. Epub 2015 Sep 26.
The present study was conducted to evaluate the diagnostic and prognostic values of serum autoantibody against matrix metalloproteinase-7 (MMP-7) in patients with oral squamous cell carcinoma (OSCC).
Anti-MMP-7 antibodies were measured in sera from 204 patients with OSCC and 212 normal controls using enzyme-linked immunosorbent assay, and clinicopathologic characteristics were correlated. Prognostic consequence was assessed with Kaplan-Meier curve and log-rank tests using Cox proportional hazard models. To check whether anti-MMP-7 antibody was related to tumor associated antigen, real-time polymerase chain reaction and western blot were used to measure MMP-7 mRNA and protein expression in tumor tissues from all 204 patients with OSCC.
Serum anti-MMP-7 antibody was higher in patients with OSCC (P < .05), and those with poorly differentiated tumors had more anti-MMP-7 antibody than those with well to moderate tumor differentiation (P < .01, P < .01, respectively). Patients with OSCC at late TNM stages (III, IV) and lymph node metastases had relatively higher serum anti-MMP-7 antibody levels than those with earlier stages (I, II) and those who lacked lymph node metastases (P < .05 for the 2 comparisons). OSCC prediction sensitivity as measured by receiver operating characteristics analysis was 0.485 and specificity was 0.896 (area under the curve, 0.761; 95% confidence interval, 0.716 to 0.806). Cox analysis showed that serum anti-MMP-7 antibody positivity independently predicted poor overall survival in patients with OSCC (hazard ratio, 1.82; 95% confidence interval, 1.07 to 4.61). MMP-7 mRNA and protein expression was increased in tumor tissues from patients with OSCC and high serum anti-MMP-7 antibody.
Serum anti-MMP-7 antibody might be a novel diagnostic and prognostic biomarker for OSCC.
本研究旨在评估血清基质金属蛋白酶-7（MMP-7）自身抗体在口腔鳞状细胞癌（OSCC）患者中的诊断和预后价值。
采用酶联免疫吸附测定法检测204例OSCC患者和212例正常对照者血清中的抗MMP-7抗体，并分析其与临床病理特征的相关性。使用Kaplan-Meier曲线和对数秩检验，通过Cox比例风险模型评估预后情况。为检测抗MMP-7抗体是否与肿瘤相关抗原有关，采用实时聚合酶链反应和蛋白质印迹法检测204例OSCC患者肿瘤组织中MMP-7 mRNA和蛋白表达。
OSCC患者血清抗MMP-7抗体水平较高（P < 0.05），肿瘤分化差的患者比肿瘤分化良好至中等的患者具有更多的抗MMP-7抗体（分别为P < 0.01，P < 0.01）。TNM分期较晚（III、IV期）且有淋巴结转移的OSCC患者血清抗MMP-7抗体水平相对高于分期较早（I、II期）且无淋巴结转移的患者（两项比较P均< 0.05）。通过受试者操作特征分析测得的OSCC预测敏感性为0.485，特异性为0.896（曲线下面积为0.761；95%置信区间为0.716至0.806）。Cox分析显示，血清抗MMP-7抗体阳性可独立预测OSCC患者总体生存率较差（风险比为1.82；95%置信区间为1.07至4.61）。OSCC患者肿瘤组织中MMP-7 mRNA和蛋白表达增加，且血清抗MMP-7抗体水平较高。
血清抗MMP-7抗体可能是OSCC一种新的诊断和预后生物标志物。
